

2026 ASCO Election COI Report – October 31, 2025

All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution

For up-to-date open payments information, please visit

<https://openpaymentsdata.cms.gov/search> and enter the candidate's name.

Neeraj Agarwal, MD, FASCO

Research Funding: Bayer (Inst), Bristol-Myers Squibb (Inst), Takeda (Inst), Pfizer (Inst), Exelixis (Inst), Amgen (Inst), AstraZeneca (Inst), Calithera Biosciences (Inst), Celldex (Inst), Eisai (Inst), Genentech (Inst), Immunomedics (Inst), Janssen (Inst), Merck (Inst), Lilly (Inst), Nektar (Inst), ORIC Pharmaceuticals (Inst), Crispr Therapeutics (Inst), Arvinas (Inst), Gilead Sciences (Inst)

Travel, Accommodations, Expenses: Pfizer, Exelixis

Last Update: 8/5/25

Melvin L.K. Chua, PhD, MBBS, FRCR, FASCO

Leadership: Digital Life Line

Stock and Other Ownership Interests: BeiGene (I), Bicara Therapeutics (I), Digital Life Line

Honoraria: Janssen Oncology, Varian, AstraZeneca, Bayer, BeiGene, Top Alliance BioScience, Novartis, Astellas Pharma, MSD, Seagen

Consulting or Advisory Role: Merck Sharp & Dohme, ImmunoSCAPE, IQVIA, BeiGene, PVmed, Axiom Healthcare Strategies, Seagen, Bicara Therapeutics, K2 Therapeutics, Heron Neutron Corp, Telix Pharmaceuticals, Novartis

Research Funding: PVmed, Decipher Biosciences, MVision, Artera, ImmunoSCAPE, BeiGene (Inst), Bayer (Inst)

Patents, Royalties, Other Intellectual Property: High Sensitivity Lateral Flow Immunoassay For Detection of Analyte in Samples (10202107837T), Singapore. (Danny Jian Hang Tng, Chua Lee Kiang Melvin, Zhang Yong, Jenny Low, Ooi Eng Eong, Soo Khee Chee)

(OPTIONAL) Uncompensated Relationships: Alice Arc, American Joint Committee on Cancer Staging

Last Update: 9/18/25

Karyn A. Goodman, MD, MS, FASTRO, FACR, FASCO

Consulting or Advisory Board: RenovoRx, Agenus, GlaxoSmithKline

Other Relationship: National Cancer Institute

Last Update: 7/13/25

Dawn L. Hershman, MD, MS, FASCO

Consulting or Advisory Role: AIM Specialty Health

Last Update: 8/26/25

Herbert Ho-fung Loong, MBBS, FRCP, FASCO

Consulting or Advisory Role: Roche/Genentech, Novartis, Boehringer-Ingelheim, Celgene, Eli-Lilly, Illumina, Guardant Health, Eisai, Takeda, Emerald Clinical Trials

Speakers' Bureau: Guardant Health, Bayer, Amgen, Astra Zeneca, Boehringer Ingelheim, Eli-Lilly, Johnson & Johnson/Janssen, Novartis

Research Funding: MSD Oncology (Inst)

Travel, Accommodations, Expenses: Roche, MSD Oncology, Bayer, Pfizer

Last Update: 8/18/25

Wells A. Messersmith, MD, FACP, FASCO

Honoraria: Research to Practice (Inst)

Consulting or Advisory Board: Amgen, Criterium (Inst)

Research Funding: AstraZeneca/MedImmune (I), Experimental Drug Development Centre (EDDC), Accent Therapeutics, Pfizer (Inst), ALX Therapeutics (Inst), Exelixis (Inst), RasCal (Inst), Agenus (Inst), Nurix (Inst), Revolution Medicines (Inst)

Last Update: 9/2/25

C. S. Pramesh, MBBS, MS, FRCS

No relationships to disclose

Last Update: 9/1/25

W. Kimryn Rathmell, MD, PhD, FASCO

Other Relationship: Sitryx (I), Merk (I)

Last Update: 7/26/25

Deborah Schrag, MD, MPH, FASCO

Stock and Other Ownership Interests: Merk (I)

Consulting or Advisory Role: Journal of the American Medical Association, Genentech

Research Funding: AACR, GRAIL

Patents, Royalties, Other Intellectual Property: PRISSMM model is trademarked and curation tools are available to academic medical centers and government under creative commons license.

Last Update: 2/12/25

Mina S. Sedrak, MD, MS, FASCO

Patents, Royalties, Other Intellectual Property: Up-to-Date

Last Update: 8/28/25

Piyush Srivastava, MD, FASCO

No relationships to disclose

Last Update: 9/13/25

Ana I. Velázquez Mañana, MD, MSc, FASCO

Honoraria: MJH Life Sciences, Curio Science, MDOutlook, Guidepoint, Onviv, Medscape

Consulting or Advisory Board: AstraZeneca Pharmaceuticals, Merus NV, Novocure, Regeneron, Abbvie, Janssen, BMS, Boehringer Ingelheim, Daiichi Sankyo

Research Funding: Janssen (Inst), Genentech/Roche (Inst)

Travel, Accommodations, Expenses: Novocure, Pfizer, Regeneron, Merus NV, Janssen

Last Update: 8/18/25

Dan Zuckerman, MD, FASCO

Leadership: OncoHealth Medical Group, PA

Consulting or Advisory Board: Oncology Analytics, AstraZeneca, Revolution Medicines

Last Update: 7/14/25